ライフサイエンスコーパス: clomiphene

1 les after exposure to oral contraceptives or clomiphene.

2 nresponsive to the induction of ovulation by clomiphene.

3 d with gonadotropin but not as compared with clomiphene.

4 min would increase the ovulatory response to clomiphene.

5 ificantly in the 25 women given placebo plus clomiphene.

6 mulative live births than those who received clomiphene (103 of 374 [27.5%] vs. 72 of 376 [19.1%], P=

7 four cycles) with gonadotropin (301 women), clomiphene (300), or letrozole (299).

8 ificantly from the rate with gonadotropin or clomiphene (42 of 192, 22%; P=0.15) or clomiphene alone

9 ion rate was higher with letrozole than with clomiphene (834 of 1352 treatment cycles [61.7%] vs. 688

10 As an example, we found that clomiphene, a recently discovered undecaprenyl diphospha

11 eening effort using this approach identified clomiphene, a widely used fertility drug, as one such co

12 in or clomiphene (42 of 192, 22%; P=0.15) or clomiphene alone (8 of 85, 9%; P=0.44) but was lower tha

13 or gonadotropin alone (P<0.001) but not with clomiphene alone (P=0.10).

14 common, unique region on HSA; cis- and trans-clomiphene also appeared to interact at a unique site, a

15 Risk was more strongly associated with clomiphene among nulligravid (RR = 3.49, 95% CI: 1.3, 9.

16 2.0 (95% confidence interval: 1.1, 3.6) for clomiphene and ART exposure, respectively.

17 Clomiphene and assisted reproductive technologies (ART)

18 herapy group (P<0.001 for metformin vs. both clomiphene and combination therapy; P=0.31 for clomiphen

19 to the observed suppressive interactions of clomiphene and in turn reveals aspects of the biology th

20 Clomiphene and insulin sensitizers are used alone and in

21 All multiple gestations in the clomiphene and letrozole groups were twins, whereas gona

22 he binding that takes place between the drug clomiphene and the protein human serum albumin (HSA).

23 ompetition experiments between cis- or trans-clomiphene and various site-selective probes indicated t

24 robe for the bilirubin site, and cisor trans-clomiphene as markers for the tamoxifen site.

25 min ovulated spontaneously or in response to clomiphene, as compared with 3 of the 26 women (12 perce

26 and 25 women in the placebo group were given clomiphene because they did not ovulate spontaneously du

27 ous site-selective probes indicated that the clomiphene-binding region is the same as the proposed ta

28 The ovulatory response to clomiphene can be increased in obese women with the poly

29 Chronic (8-12 wk) administration of clomiphene citrate caused no increase in serum FSH or LH

30 ith the polycystic ovary syndrome to receive clomiphene citrate plus placebo, extended-release metfor

31 Clomiphene citrate, a selective estrogen receptor modula

32 h unexplained infertility is gonadotropin or clomiphene citrate.

33 ulate spontaneously were then given 50 mg of clomiphene daily for five days while continuing to take

34 to interact at a unique site, although trans-clomiphene displayed additional direct competition with

35 Uterine cancer risk increased with clomiphene dose (RR = 1.93, 95% CI: 0.9, 4.0 for >900 mg

36 For clomiphene exposure without ART use, the direct effect e

37 s placebo, or a combination of metformin and clomiphene for up to 6 months.

38 men, in a 1:1 ratio, to receive letrozole or clomiphene for up to five treatment cycles, with visits

39 arin-azapropazone site of HSA, and cis/trans-clomiphene gave positive allosteric effects caused by th

40 e metformin group (21.7%) than in either the clomiphene group (39.5%, P=0.002) or the combination-the

41 ies in the letrozole group versus one in the clomiphene group (P=0.65).

42 oup [31.8%] and 30 of 103 pregnancies in the clomiphene group [29.1%]) or twin pregnancy (3.4% and 7.

43 e rate of multiple pregnancy was 6.0% in the clomiphene group, 0% in the metformin group, and 3.1% in

44 h rate was 22.5% (47 of 209 subjects) in the clomiphene group, 7.2% (15 of 208) in the metformin grou

45 frequent, in the metformin group than in the clomiphene group.

46 nd in these studies that both cis- and trans-clomiphene have 1:1 interactions at a common binding reg

47 he association equilibrium constants for the clomiphene/HSA system, with beta-cyclodextrin being used

48 Clomiphene is superior to metformin in achieving live bi

49 Clomiphene is the current first-line infertility treatme

50 As compared with clomiphene, letrozole was associated with higher live-bi

51 Study results suggest that clomiphene may increase uterine cancer risk (rate ratio

52 Clomiphene may increase uterine cancer risk, with higher

53 ndings suggest that relatively little of the clomiphene-NTD association is mediated through the pathw

54 After treatment with gonadotropin, clomiphene, or letrozole, clinical pregnancies occurred

55 men (90 percent) who received metformin plus clomiphene ovulated (mean peak serum progesterone concen

56 women (8 percent) who received placebo plus clomiphene ovulated (P<0.001).

57 rates with standard therapy (gonadotropin or clomiphene) (P=0.003) or gonadotropin alone (P<0.001) bu

58 Importantly, clomiphene represents a lead for antibacterial drug disc

59 Among the 21 women given metformin plus clomiphene, the mean (+/-SE) area under the serum insuli

60 necessary to clarify the association between clomiphene use and uterine cancer.

61 omiphene and combination therapy; P=0.31 for clomiphene vs. combination therapy).

62 Specifically, ever use of clomiphene was associated with a 1.6-fold increased risk

63 Clomiphene was associated with a higher incidence of hot

64 prove the water solubility of cis- and trans-clomiphene without affecting the nature of their binding

65 We considered exposures to clomiphene (without ART) and ART during the periconcepti